Clinical trial data show side effects and interruption rates have rocked: 40% drop in Wall Street.
A Viking Therapeutics made a clinical trial of a new Obesity tablet. But the process ran badly – Whether at the clinical level or at the level of the bag.
In the study, the pill – diary – from Viking helped patients to lose up to 12.2% of the weight in about three months. And they could still lose more weight in a long -term study.
The results have already been quickly compared to other large pharmaceutical companies: Eli Lilly and Novo Nordisk; And they seem inferior to the oral medicine of the Eli Lilly In almost all parameters, from the time in the amount of patients who have lost weight (12.4%, slightly higher in Eli).
There were two problems Essentials in the study of Viking Therapeutics: Almost one third (28%) interrupted the use of the drug during the 13 weeks of the study; and the side effects Gastrointestinal (which originated most interruptions), although most were light or moderate, and verified early in treatment. Nausea and vomiting were the most frequent symptoms.
And the company already broke in . This Tuesday the actions of Viking Therapeutics about 40% fell. This after the dissemination of the results of this clinical trial.
It points out that this essay can be a stroke for Viking – which has already been classified as a promising target of mergers and acquisitions.
May even have an unwanted outcome: the Eli Lilly and Novo Nordisk can more dominate the pharmaceutical sector. Both are also developing weight loss tablets; tablets that can reach the market years before the Viking tablet.
In fact, this essay “probably ended the hopes of Viking of becoming a great player In the tablet market for obesity in the short term, ”summarized Jared Holz, an stock expert.
